Table S1. Clinical characteristics of serum
Characteristics
Number of patients
Sex (M/F)
Age (mean ± S.D.)
Normal group
9
6 (66.6%) / 3 (33.3%)
38.08 ± 12.71
Figure S1. Nano-LC/ESI-MS and MS/MS results confirming the peptide sequence
EEDGDLQCLCVK representing a minor PF4 isoform. Precursor ion for MS/MS analysis was
doubly charged. Cysteine is carbamidomethylated.
Figure S2. Nano-LC/ESI-MS and MS/MS results confirming the peptide sequence
AEEDGDLQCLCVK representing a minor PF4 isoform. Precursor ion for MS/MS analysis was
doubly charged. Cysteine is carbamidomethylated.
Figure S3. Nano-LC/ESI-MS and MS/MS results confirming the peptide sequence
EAEEDGDLQCLCVK representing the major N-terminally variant PF4 isoform designated
Prot-p1. Precursor ion for MS/MS analysis was doubly charged. Cysteine is
carbamidomethylated.
Figure S4. Nano-LC/ESI-MS and MS/MS results confirming the peptide sequence
AEAEEDGDLQCLCVK representing the N-terminally variant PF4 isoform designated Prot-p2.
Precursor ion for MS/MS analysis was doubly charged. Cysteine is carbamidomethylated.
Figure S5. Nano-LC/ESI-MS and MS/MS results confirming the peptide sequence
SAEAEEDGDLQCLCVK representing the N-terminally variant PF4 isoform designated Prot-p3.
Precursor ion for MS/MS analysis was doubly charged. Cysteine is carbamidomethylated.
Figure S6. Nano-LC/ESI-MS and MS/MS results confirming the peptide sequence
ASAEAEEDGDLQCLCVK representing a minor PF4 isoform. Precursor ion for MS/MS
analysis was doubly charged. Cysteine is carbamidomethylated.
Figure S7. Nano-LC/ESI-MS and MS/MS results confirming the peptide sequence
FASAEAEEDGDLQCLCVK representing the N-terminally variant PF4 isoform designated
Prot-p4. Precursor ion for MS/MS analysis was doubly charged. Cysteine is
carbamidomethylated.
Figure S8. Comparison of amino acid sequences of PF4var1 (top rows) and PF4 (bottom rows).
Asterisks denote differences between the two amino acid sequences.
Figure S9. Nano-LC/ESI-MS and MS/MS results confirming a peptide sequence (AP)
representative of all PF4 (but not PF4var1) isoforms. Precursor ion for MS/MS analysis was
doubly charged. Cysteine is carbamidomethylated.
Figure S10. Nano-LC/ESI-MS and MS/MS results confirming a peptide sequence (AL)
representative of all PF4var1 (but not PF4) isoforms. Precursor ion for MS/MS analysis was
doubly charged. Cysteine is carbamidomethylated.
Figure S11. Determination of PF4-containing fractions of the C8 reversed-phase
chromatographic separation. A 20-µL aliquot of a pooled serum sample was separated by C8
reversed-phase HPLC with fractions collected every 30 s. All fractions with retention times
between 6.5 and 40 min (67 fractions in total) were evaluated for the presence of PF4. PF4 and
its isoforms were present in fractions eluted between 18.5 and 21.5 min.